Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company. The combined business will operate as Supernus and trade on the Nasdaq Global Market under the ticker symbol “SUPN.” The companies expect to close the merger during the fourth quarter of 2026. Executive Leadership And Corporate Governance Jack Khattar, President and CEO of Supernus, will serve as President, CEO, and Board member of the combined entity. Tony Kingsley, currently an Indivior director, will serve as Board Chair. Read Also: AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger Strategic Portfolio And Growth Metrics The deal unites 11 differentiated commercial medicines across psychiatry, neurology and addi...